Wednesday, April 22, 2026
← Back to archivePolicy
Policy•Fierce Pharma•Apr 22, 2026
Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
background ▾
- •Pfizer's chief strategy and innovation officer Andrew Baum is stepping down after a brief ~2-year tenure
Pfizer
→ Read original articlePolicy•STAT News•Apr 22, 2026
Opinion: Behind every miracle drug is a story
background ▾
AmbienOzempic
→ Read original articlePolicy•STAT News•Apr 22, 2026
Opinion: NASA’s plans for living in space should prioritize immunology and infectious disease
background ▾
- •This is an opinion editorial, not reporting of policy or regulatory action; it advocates for NASA consideration of immunology/infectious disease but does not represent confirmed agency priorities or decisions
Policy•STAT News•Apr 22, 2026
Opinion: The CDC’s ‘disease detective’ program turns 75
background ▾
- •The EIS program has trained over 4,300 disease detectives over 75 years and played central roles in investigating major outbreaks including COVID-19, providing critical epidemiological data that shapes drug development and public health response strategies
Policy•KFF•Apr 21, 2026
Breaking Down the U.S. Global Health Budget by Program Area
background ▾
- •U.S. global health funding has declined to $11.3 billion in FY 2026 (lowest since FY 2020 excluding emergency funding), down from a peak of $12.9 billion in FY 2023
Market Access
Market Access•Fierce Pharma•Apr 22, 2026
The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill
background ▾
- •Two major oral GLP-1 competitors are now in active head-to-head market competition following recent launches
- •Real-world prescription and market-share tracking is becoming a standard monitoring tool for this competitive segment
Novo NordiskEli LillyWegovyFoundayo
→ Read original articleMarket Access•Fierce Biotech•Apr 21, 2026
Ray Therapeutics shines a light on $125M round targeting genetic eye therapy
background ▾
- •RTx-015 received FDA RMAT designation for retinitis pigmentosa, enabling intensive FDA guidance, rolling review, and priority review eligibility—de-risking the clinical and regulatory pathway
- •Oversubscribed $125M Series B signals strong investor confidence in Ray's platform despite competitive setbacks in RP space (J&J's failed Phase 3, MeiraGTx acquisition)
- •Watch for RTx-015 clinical data readouts and FDA interactions under rolling review; monitor competitive landscape as Ocugen pursues Phase 3 completion and rolling submission in RP
Ray TherapeuticsJanus Henderson InvestorsAdage Capital ManagementRTx-015
→ Read original articleMarket Access•Fierce Pharma•Apr 22, 2026
UCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition deserts
background ▾
- •UCB is expanding patient support programs beyond traditional disease management into nutrition assistance for MG patients
UCBMyasthenia Gravis Foundation of AmericaFactor Meals
→ Read original articleMarket Access•STAT News•Apr 22, 2026
Are MAHA snacks really better for you? Nutrition experts parse a grocery aisle gold rush
background ▾
- •The $156 billion packaged snack industry is pursuing reformulation strategies (reduced sugar/dyes, added protein/fiber) to capture demand from health-conscious consumers and MAHA-aligned shoppers, but nutrition experts question whether these changes materially improve health outcomes or simply enable continued ultra-processed food consumption.
PepsiCoKraft HeinzKellanov
→ Read original articleMarket Access•Endpoints News•Apr 21, 2026
Medicare indefinitely delays pilot plan to cover weight loss drugs
background ▾
- •CMS indefinitely postponed its obesity medication coverage pilot program after insurance plans raised implementation concerns, removing near-term certainty for Medicare reimbursement of weight loss drugs
- •The delay directly impacts GLP-1 agonist manufacturers' market access strategies for Medicare beneficiaries, a substantial patient population representing significant commercial opportunity
- •Monitor for CMS policy announcements on alternative approaches to Medicare obesity drug coverage and payer feedback on acceptable program structures
Centers for Medicare and Medicaid ServicesGLP-1 receptor agonists
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•Apr 22, 2026
Roche’s Enspryng cuts relapse risk by 68% in rare neuroinflammatory disease
background ▾
- •Enspryng demonstrated 68% relapse risk reduction in Phase 3 MOGAD trial—a statistically and clinically meaningful result that could support first-in-class indication
- •This addresses a rare disease with no currently approved therapies, where patients are managed off-label, representing significant unmet medical need and potential commercial opportunity
- •Regulatory approval timeline and FDA's receptiveness to this indication remain uncertain; manufacturing scale-up and post-approval surveillance strategy should be monitored
RocheEnspryngsatralizumab
→ Read original articleClinical Trials•Fierce Biotech•Apr 22, 2026
Novartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trial
background ▾
- •Abelacimab failed to beat Eliquis in a 1,150-patient phase 3 trial for cancer-associated thrombosis, leading to termination of both CAT and VTE programs
- •Novartis paid $925M to reacquire abelacimab from Anthos in February 2025, betting on factor XI inhibitor potential despite recent class setbacks from competitors (Bayer's asundexian showed 2x mortality increase vs. Eliquis; BMS/J&J's milvexian failed phase 3)
- •Watch for 2028 approval filing readout for atrial fibrillation indication and comparative efficacy/safety data vs. DOACs; monitor Bayer's asundexian approval trajectory as a competitive benchmark
NovartisBristol Myers SquibbPfizerabelacimabEliquisFragmin
→ Read original articleClinical Trials•Fierce Biotech•Apr 21, 2026
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
background ▾
- •Welireg's first-line failure contradicts positive phase 3 data in refractory (Litespark-011, -005) and adjuvant (Litespark-022) settings, creating significant uncertainty about the drug's role and peak sales potential (previously estimated ~$2.6B)
- •Even the positive Litespark-011 and -022 data carry limitations: OS not statistically significant in second-line, and adjuvant DFS benefit may not justify broad use given concerns about over-treatment in a largely-cured patient population
- •Competitive implications: rival HIF-2α inhibitor casdatifan (Arcus/Gilead) landscape changes; timing of Merck's FDA review (target Oct. 4, 2026 for second-line indication) now uncertain pending regulatory strategy reassessment
Merck & Co.NovartisArcus BiosciencesWeliregKeytrudaLenvima
→ Read original articleClinical Trials•Fierce Biotech•Apr 21, 2026
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
background ▾
- •Daraxonrasib demonstrates competitive efficacy in first-line metastatic pancreatic cancer (47% ORR alone, 58% with chemotherapy) following recent phase 3 second-line success, supporting accelerated development in earlier lines of therapy
- •Revolution's platform targets Ras via novel 'glue' mechanism binding to cyclophilin A—mechanistically distinct from approved Lumakras and Krazati—addressing a historically undruggable oncogene across multiple mutation types
- •Watch for phase 3 trial initiation/readouts for daraxonrasib in first-line pancreatic cancer and zoldonrasib in lung cancer; clarity on how safety/combination profiles differentiate the two candidates in head-to-head clinical scenarios
Revolution MedicinesAmgenBristol Myers SquibbdaraxonrasibzoldonrasibLumakras
→ Read original articleClinical Trials•Fierce Biotech•Apr 21, 2026
Roche unpacks death imbalance, secondary endpoints in phase 3 multiple sclerosis trials
background ▾
- •Fenebrutinib showed an 8:1 death imbalance versus Aubagio across two phase 3 RMS trials, with heterogeneous causes (infections, diabetes complications, accident) that Roche attributed to unrelated etiologies rather than drug effect.
- •Secondary endpoints demonstrated robust efficacy on inflammation markers (70.7%-77.6% reduction) and disease burden (76%-82.5% reduction), but disability progression benefits were numerically rather than statistically significant versus Aubagio.
- •Regulatory submission planned for RMS and PPMS data; mortality signal and ambiguous disability results will likely invite close regulatory scrutiny and may impact market positioning relative to Novartis' potentially safer BTK inhibitor in development.
RocheSanofiNovartisfenebrutinibAubagioOcrevus
→ Read original article